Key clinical point: Studies show that clinical benefits can come from nonabstinence drinking reduction.
Major finding: Those achieving a reduction of just a few drinks a day can significantly improve in adverse consequences, mental health, and other outcomes.
Study details: Randomized trial of more than 1,000 patients treated with acamprosate, naltrexone, and psychological intervention.
Disclosures: Dr. Anton reported consulting and/or funding from Alkermes, Allergan, Indivior, Insys Life Epigenetics, and Laboratori Farmaceutico CT. Dr. O’Malley reported consulting and/or funding from Alkermes, Amygdala, Indivior, Mistubishi Tanabe, Opiant, and other sources. Dr. Falk reported no disclosures.
REPORTING FROM AAAP 2018
Must Reads in Addiction Medicine
Eating Disorders and Substance Use in Adolescents, Int J Eat Disord; ePub 2019 Jan 14; Kirkpatrick, et al
Young Adult Patterns of Marijuana Use in the US, Addiction; ePub 2019 Jan 4; Terry-McElrath, et al
Sexual Minority Youth and Substance Use Patterns, Arch Sex Behav; ePub 2019 Jan 2; Talley, et al